查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1818079

2032 年生技药品和生物相似药市场预测：按产品类型、治疗领域、製造商、分销管道、最终用户和地区进行的全球分析

Biologics & Biosimilars Market Forecasts to 2032 - Global Analysis By Product Type, Therapeutic Area, Manufacturing Source, Distribution Channel, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球生技药品和生物相似药市场预计在 2025 年达到 5,382 亿美元，到 2032 年将达到 1,2198.6 亿美元，预测期内复合年增长率为 12.4%。

生技药品是指利用活细胞或生物体製造的创新疗法，例如单株抗体、蛋白质和疫苗，用于治疗慢性和严重。生物相似药是在生技药品专利保护到期后研发的，其安全性、有效性和品质与生物製剂相似，从而确保相同的治疗效果。这些经济高效的选择扩大了患者获得重要疗法的管道。生技药品和生物相似药协同作用，透过推进医疗解决方案、降低治疗成本和改善整体临床疗效，提升医疗保健水准。

慢性病增多

在全球范围内，癌症、糖尿病和自体免疫疾病等慢性疾病的发生率不断上升，推动了对生技药品和生物相似药的需求。医疗保健系统优先考虑能够提高疗效、减少副作用的长期治疗方案。具有标靶作用机制的生技药品正成为疾病管理策略的核心。随着患者群体老化和诊断能力的提高，对生技药品的需求持续增长。生物相似药作为一种经济高效的替代方案，正日益受到青睐，尤其是在医疗保健预算紧张的市场。这种日益增长的需求正在加速整个生物製药产业的创新和投资。

开发和製造成本高

生技药品和生物相似药的开发涉及从细胞株工程到纯化和验证的复杂流程。严格的监管要求和漫长的临床试验时间进一步加剧了高成本。生产设施必须满足严格的品质标准，并且通常需要专业的基础设施和熟练的人员。低温运输物流和污染控制的需求进一步增加了营运成本。规模较小的公司面临进入壁垒，限制了竞争，并减缓了市场扩张。因此，定价仍然是一个挑战，尤其是在新兴国家。

研发和製造领域的技术进步

先进的分析技术和人工智慧驱动的建模技术正在加速药物研发并缩短开发週期。细胞培养基和表达系统的创新正在提高产量和产品一致性。自动化数位双胞胎正被用于优化设施运营并减少人为错误。这些进步正在降低成本，并实现复杂生技药品的可扩展生产。随着技术的成熟，提供具有竞争力的生物相似药产品的公司得以进入市场。

激烈的竞争和价格压力

专利到期导致多家製药公司进入该领域，加剧了价格竞争。法规虽然不断发展，但仍是阻碍市场进入和增加合规成本的障碍。付款人和医疗保健提供者要求降低价格，从而挤压了整个价值链的利润率。品牌忠诚度和医生对生物相似药的犹豫也影响了采用率。如果没有差​​异化和策略定位，企业将在日益商品化的环境中面临失去市场份额的风险。

COVID-19的影响

疫情扰乱了生技药品和生物相似药的临床试验、供应链和生产流程。封锁措施以及疫苗和紧急治疗资源的重新分配，推迟了与新冠疫情无关的产品上市。然而，这场危机凸显了生技药品在管理感染疾病和免疫反应的重要性。生物製药公司加速数位转型，并采用远端监控和分散式检测模式。各国政府和监管机构引入了灵活的框架，以维持药物研发的连续性。疫情后的策略越来越强调生技药品生产的韧性、敏捷性和全球协作。

生技药品领域预计将成为预测期内最大的细分市场

由于疗效卓越且适应症不断扩展，生技药品领域预计将在预测期内占据最大市场份额。单株抗体、重组蛋白和基因疗法正在获得广泛的临床认可。复杂疾病的日益普及推动了对生物目标疗法的需求。在可靠的临床数据和患者接受度的支持下，监管核准正在加速。生技药品的研发投入持续超过其他领域，巩固了其市场领先地位。随着生技药品的普及，其在全球生技药品支出中的份额预计将稳步上升。

生物製药公司部门预计在预测期内以最高复合年增长率成长

在积极创新和产品线不断拓展的推动下，生物製药公司预计将在预测期内实现最高成长率。这些公司利用先进的平台进行生技药品的合成、配製和递送。战略联盟和许可协议使其能够更快地进入市场并扩大地域覆盖范围。生物製药公司也正在投资生物相似药组合，以抓住专利到期后的机会。他们的敏捷性和对利基疗法的专注使其在持续成长方面占据有利地位。在个人化医疗需求日益增长的背景下，生物製药公司在生技药品开发方面处于主导。

比最大的地区

受医疗保健支出成长和患者人数不断增加的推动，预计亚太地区将在预测期内占据最大的市场份额。中国、印度和韩国等国家正在大力投资，以更新生技药品基础设施和法规。国内製造商正在扩大生产规模，以满足国内和出口需求。政府倡议正在推动生物相似药的推广应用，以降低治疗成本。临床试验活动蓬勃发展，亚太地区正逐渐成为生技药品研究的中心。该地区的人口和经济动态是该行业的关键成长引擎。

复合年增长率最高的地区

在技​​术领先地位和强劲的生物製药投资的推动下，北美预计将在预测期内实现最高的复合年增长率。美国和加拿大正在透过产学研合作和联邦资金推动生技药品创新。监管机构正在简化生物相似药的核准途径，鼓励市场竞争。精准医疗和生技药品的应用正在各个治疗领域加速发展。数位健康整合和人工智慧主导的药物开发正在提高效率和疗效。

免费客製化服务

此报告的订阅者可以选择以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球生技药品和生物相似药市场（依产品类型）

  • 生技药品
    • 单株抗体
    • 重组蛋白
    • 荷尔蒙
    • 疫苗
    • 细胞激素和干扰素
    • 融合蛋白
  • 生物相似药
    • 单株抗体生物相似药
    • 低分子量肝素
    • 重组荷尔蒙生物相似药
    • 免疫调节药物
    • 抗发炎生物相似药

6. 全球生技药品和生物相似药市场（依治疗领域）

  • 肿瘤学
  • 眼科
  • 自体免疫疾病
  • 心血管系统
  • 内分泌学
  • 感染疾病
  • 血液学
  • 创伤治疗和再生护理

7. 全球生技药品和生物相似药市场（按製造商）

  • 哺乳动物细胞培养
  • 酵母表现系统
  • 细菌细胞培养
  • 基因改造模型

8. 全球生技药品和生物相似药市场（按分销管道）

  • 医院药房
  • 专科诊所
  • 零售药局
  • 网路药局

9. 全球生技药品和生物相似药市场（按最终用户划分）

  • 医院
  • 诊断实验室
  • 研究所
  • 生物製药公司
  • 其他的

10. 全球生技药品和生物相似药市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Amgen
  • Sanofi
  • Pfizer
  • Eli Lilly
  • Novartis
  • Viatris
  • Biocon Biologics
  • AbbVie
  • Samsung Bioepis
  • Teva Pharmaceuticals
  • Celltrion
  • Fresenius Kabi
  • Roche
  • Boehringer Ingelheim
  • Merck KGaA
Product Code: SMRC31042

According to Stratistics MRC, the Global Biologics & Biosimilars Market is accounted for $538.20 billion in 2025 and is expected to reach $1219.86 billion by 2032 growing at a CAGR of 12.4% during the forecast period. Biologics are innovative therapies produced using living cells or organisms, such as monoclonal antibodies, proteins, and vaccines, that target chronic and severe diseases. Biosimilars, created after biologics lose patent protection, are close replicas in terms of safety, efficacy, and quality, ensuring similar therapeutic effects. These cost-effective options expand patient access to critical treatments. Together, biologics and biosimilars enhance healthcare by advancing medical solutions, reducing treatment costs, and improving overall clinical outcomes.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The increasing global burden of chronic illnesses such as cancer, diabetes, and autoimmune disorders is fuelling demand for biologics and biosimilars. Healthcare systems are prioritizing long-term treatment solutions that offer improved efficacy and reduced side effects. Biologics, with their targeted mechanisms, are becoming central to disease management strategies. As patient population's age and diagnostic capabilities improve, the need for biologic therapies continues to rise. Biosimilars are gaining traction as cost-effective alternatives, especially in markets with strained healthcare budgets. This growing demand is accelerating innovation and investment across the biopharmaceutical landscape.

Restraint:

High development and manufacturing costs

Developing biologics and biosimilars involves complex processes, from cell line engineering to purification and validation. These high costs are compounded by stringent regulatory requirements and extended clinical trial timelines. Manufacturing facilities must meet rigorous quality standards, often requiring specialized infrastructure and skilled personnel. The need for cold chain logistics and contamination control further increases operational expenses. Smaller firms face barriers to entry, limiting competition and slowing market expansion. As a result, pricing remains a challenge, especially in emerging economies.

Opportunity:

Technological advancements in R&D and manufacturing

Advanced analytics and AI-driven modelling are enhancing drug discovery and reducing development timelines. Innovations in cell culture media and expression systems are improving yield and product consistency. Automation and digital twins are being adopted to optimize facility operations and reduce human error. These advancements are lowering costs and enabling scalable production of complex biologics. As technology matures, more players can enter the market with competitive biosimilar offerings.

Threat:

Intense competition and pricing pressure

Patent expirations are opening the door to multiple entrants, intensifying pricing battles. Regulatory pathways, while evolving, still pose hurdles that delay market access and increase compliance costs. Payers and healthcare providers are demanding lower prices, squeezing margins across the value chain. Brand loyalty and physician hesitancy toward biosimilars also impact adoption rates. Without differentiation and strategic positioning, companies risk losing market share in an increasingly commoditized landscape.

Covid-19 Impact

The pandemic disrupted clinical trials, supply chains, and manufacturing schedules for biologics and biosimilars. Lockdowns and resource reallocation toward vaccines and emergency treatments delayed non-COVID product launches. However, the crisis also highlighted the importance of biologics in managing infectious diseases and immune responses. Biopharma companies accelerated digital transformation, adopting remote monitoring and decentralized trial models. Governments and regulators introduced flexible frameworks to maintain continuity in drug development. Post-pandemic strategies now emphasize resilience, agility, and global collaboration in biologics manufacturing.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period, its superior therapeutic outcomes and expanding indications. Monoclonal antibodies, recombinant proteins, and gene therapies are gaining widespread clinical acceptance. Increasing prevalence of complex diseases is driving demand for targeted biologic treatments. Regulatory approvals are accelerating, supported by robust clinical data and patient advocacy. Investment in biologics R&D continues to outpace other segments, reinforcing its market leadership. As biologics become more accessible, their share in global pharmaceutical spending is expected to rise steadily.

The biopharma companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biopharma companies segment is predicted to witness the highest growth rate, driven by aggressive innovation and pipeline expansion. These firms are leveraging advanced platforms for biologic synthesis, formulation, and delivery. Strategic collaborations and licensing agreements are enabling faster market entry and broader geographic reach. Biopharma players are also investing in biosimilar portfolios to capture post-patent opportunities. Their agility and focus on niche therapies position them well for sustained growth. As demand for personalized medicine increases, biopharma companies are leading the charge in biologics development.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare expenditure and expanding patient populations. Countries like China, India, and South Korea are investing heavily in biologics infrastructure and regulatory modernization. Local manufacturers are scaling up production to meet domestic and export demand. Government initiatives are promoting biosimilar adoption to reduce treatment costs. Clinical trial activity is surging, with Asia Pacific emerging as a hub for biologics research. The region's demographic and economic dynamics make it a key growth engine for the industry.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, furled by technological leadership and robust biopharma investment. The U.S. and Canada are advancing biologics innovation through academic-industry partnerships and federal funding. Regulatory agencies are streamlining approval pathways for biosimilars, encouraging market competition. Adoption of precision medicine and biologic therapies is accelerating across therapeutic areas. Digital health integration and AI-driven drug development are enhancing efficiency and outcomes.

Key players in the market

Some of the key players profiled in the Biologics & Biosimilars Market include Amgen, Sanofi, Pfizer, Eli Lilly, Novartis, Viatris, Biocon Biologics, AbbVie, Samsung Bioepis, Teva Pharmaceuticals, Celltrion, Fresenius Kabi, Roche, Boehringer Ingelheim, and Merck KGaA.

Key Developments:

In September 2025, Novartis AG has reached an agreement to purchase the New York-based firm, Tourmaline Bio Inc., in a deal valued at a staggering $1.4 billion. This move is aimed at reducing systemic inflammation, which is termed a major driver of cardiovascular disease. Novartis has been on the lookout for deals that would amplify its sales beyond 2025.

In August 2025, Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer's disease. In addition, the acquisition of Vigil's preclinical pipeline will further strengthen Sanofi's research in various neurodegenerative diseases.

Product Types Covered:

  • Biologics
  • Biosimilars

Therapeutic Areas Covered:

  • Oncology
  • Ophthalmology
  • Autoimmune Disorders
  • Cardiovascular
  • Endocrinology
  • Infectious Diseases
  • Hematology
  • Wound Healing & Regenerative Care

Manufacturing Sources Covered:

  • Mammalian Cell Culture
  • Yeast Expression Systems
  • Bacterial Cell Culture
  • Transgenic Models

Distribution Channels Covered:

  • Hospital Pharmacies
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Diagnostic Labs
  • Research Institutes
  • Biopharma Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biologics & Biosimilars Market, By Product Type

  • 5.1 Introduction
  • 5.2 Biologics
    • 5.2.1 Monoclonal Antibodies
    • 5.2.2 Recombinant Proteins
    • 5.2.3 Hormones
    • 5.2.4 Vaccines
    • 5.2.5 Cytokines & Interferons
    • 5.2.6 Fusion Proteins
  • 5.3 Biosimilars
    • 5.3.1 Monoclonal Antibody Biosimilars
    • 5.3.2 Low Molecular Weight Heparins
    • 5.3.3 Recombinant Hormone Biosimilars
    • 5.3.4 Immunomodulators
    • 5.3.5 Anti-inflammatory Biosimilars

6 Global Biologics & Biosimilars Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Ophthalmology
  • 6.4 Autoimmune Disorders
  • 6.5 Cardiovascular
  • 6.6 Endocrinology
  • 6.7 Infectious Diseases
  • 6.8 Hematology
  • 6.9 Wound Healing & Regenerative Care

7 Global Biologics & Biosimilars Market, By Manufacturing Source

  • 7.1 Introduction
  • 7.2 Mammalian Cell Culture
  • 7.3 Yeast Expression Systems
  • 7.4 Bacterial Cell Culture
  • 7.5 Transgenic Models

8 Global Biologics & Biosimilars Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Specialty Clinics
  • 8.4 Retail Pharmacies
  • 8.5 Online Pharmacies

9 Global Biologics & Biosimilars Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Labs
  • 9.4 Research Institutes
  • 9.5 Biopharma Companies
  • 9.6 Other End Users

10 Global Biologics & Biosimilars Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen
  • 12.2 Sanofi
  • 12.3 Pfizer
  • 12.4 Eli Lilly
  • 12.5 Novartis
  • 12.6 Viatris
  • 12.7 Biocon Biologics
  • 12.8 AbbVie
  • 12.9 Samsung Bioepis
  • 12.10 Teva Pharmaceuticals
  • 12.11 Celltrion
  • 12.12 Fresenius Kabi
  • 12.13 Roche
  • 12.14 Boehringer Ingelheim
  • 12.15 Merck KGaA

List of Tables

  • Table 1 Global Biologics & Biosimilars Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Biologics & Biosimilars Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Biologics & Biosimilars Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 4 Global Biologics & Biosimilars Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 5 Global Biologics & Biosimilars Market Outlook, By Recombinant Proteins (2024-2032) ($MN)
  • Table 6 Global Biologics & Biosimilars Market Outlook, By Hormones (2024-2032) ($MN)
  • Table 7 Global Biologics & Biosimilars Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 8 Global Biologics & Biosimilars Market Outlook, By Cytokines & Interferons (2024-2032) ($MN)
  • Table 9 Global Biologics & Biosimilars Market Outlook, By Fusion Proteins (2024-2032) ($MN)
  • Table 10 Global Biologics & Biosimilars Market Outlook, By Biosimilars (2024-2032) ($MN)
  • Table 11 Global Biologics & Biosimilars Market Outlook, By Monoclonal Antibody Biosimilars (2024-2032) ($MN)
  • Table 12 Global Biologics & Biosimilars Market Outlook, By Low Molecular Weight Heparins (2024-2032) ($MN)
  • Table 13 Global Biologics & Biosimilars Market Outlook, By Recombinant Hormone Biosimilars (2024-2032) ($MN)
  • Table 14 Global Biologics & Biosimilars Market Outlook, By Immunomodulators (2024-2032) ($MN)
  • Table 15 Global Biologics & Biosimilars Market Outlook, By Anti-inflammatory Biosimilars (2024-2032) ($MN)
  • Table 16 Global Biologics & Biosimilars Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 17 Global Biologics & Biosimilars Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 18 Global Biologics & Biosimilars Market Outlook, By Ophthalmology (2024-2032) ($MN)
  • Table 19 Global Biologics & Biosimilars Market Outlook, By Autoimmune Disorders (2024-2032) ($MN)
  • Table 20 Global Biologics & Biosimilars Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 21 Global Biologics & Biosimilars Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 22 Global Biologics & Biosimilars Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Biologics & Biosimilars Market Outlook, By Hematology (2024-2032) ($MN)
  • Table 24 Global Biologics & Biosimilars Market Outlook, By Wound Healing & Regenerative Care (2024-2032) ($MN)
  • Table 25 Global Biologics & Biosimilars Market Outlook, By Manufacturing Source (2024-2032) ($MN)
  • Table 26 Global Biologics & Biosimilars Market Outlook, By Mammalian Cell Culture (2024-2032) ($MN)
  • Table 27 Global Biologics & Biosimilars Market Outlook, By Yeast Expression Systems (2024-2032) ($MN)
  • Table 28 Global Biologics & Biosimilars Market Outlook, By Bacterial Cell Culture (2024-2032) ($MN)
  • Table 29 Global Biologics & Biosimilars Market Outlook, By Transgenic Models (2024-2032) ($MN)
  • Table 30 Global Biologics & Biosimilars Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 31 Global Biologics & Biosimilars Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 32 Global Biologics & Biosimilars Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 33 Global Biologics & Biosimilars Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 34 Global Biologics & Biosimilars Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 35 Global Biologics & Biosimilars Market Outlook, By End User (2024-2032) ($MN)
  • Table 36 Global Biologics & Biosimilars Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 37 Global Biologics & Biosimilars Market Outlook, By Diagnostic Labs (2024-2032) ($MN)
  • Table 38 Global Biologics & Biosimilars Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 39 Global Biologics & Biosimilars Market Outlook, By Biopharma Companies (2024-2032) ($MN)
  • Table 40 Global Biologics & Biosimilars Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.